Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2012 Oct 21;18(39):5504-13. doi: 10.3748/wjg.v18.i39.5504.

Molecular targets in the treatment of alcoholic hepatitis.

Author information

1
Department of Liver Medicine, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom.

Abstract

Alcohol related costs to health and society are high. One of the most serious complications of alcohol misuse to the individual is the development of alcoholic hepatitis (AH), a clinical syndrome of jaundice and progressive inflammatory liver injury in patients with a history of recent heavy alcohol use. It has a poor outcome and few existing successful therapies. The use of glucocorticoids in patients with severe AH is still controversial and there remains a group of patients with glucocorticoid-resistant disease. However, as our understanding of the pathogenesis of the condition improves there are opportunities to develop new targeted therapies with specific actions to control liver inflammation without having a detrimental effect on the immune system as a whole. In this article we review the molecular mechanisms of AH concentrating on the activation of the innate and adaptive immune response. We consider existing treatments including glucocorticoids, anti-tumor necrosis factor therapy and pentoxifylline and their limitations. Using our knowledge of the disease pathogenesis we discuss possible novel therapeutic approaches. New targets include pro-inflammatory cytokines such as interleukin (IL)-17, chemokines and their receptors (for example IL-8, CXCL9 and CXCR3) and augmentation of anti-inflammatory molecules such as IL-10 and IL-22. And there is also future potential to consider combination therapy to selectively modulate the immune response and gain control of disease.

KEYWORDS:

Alcoholic hepatitis; Chemokine receptors; Interleukins; Pentoxifylline; Tumour necrosis factor-α

PMID:
23112542
PMCID:
PMC3482636
DOI:
10.3748/wjg.v18.i39.5504
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Support Center